Tuesday, 11 May, 2021 - 14:00
Hiremii slumps on ASX debut
Shares in recruitment firm Hiremii dropped in value by close to 30 per cent today following an overall slump for tech stocks on the ASX.
Argenica Therapeutics is a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury & neurodegenerative diseases.
Rank | Company | 1 Yr | 5 Yr |
---|---|---|---|
241st | West African Resources | 62.03% | 31.18% |
242nd | St Barbara | 61.96% | -20.43% |
243rd | Argenica Therapeutics | 61.63% | 0% |
244th | Mako Gold | 61.19% | -28.92% |
245th | Polynovo | 60% | 4.21% |
Rank | Company | # | |
---|---|---|---|
142nd | ![]() |
Argenica Therapeutics | $2.60m |
143rd | ![]() |
Elsight | $2.55m |
144th | ![]() |
Osteopore | $2.41m |
145th | ![]() |
NeuroScientific Biopharmaceuticals | $2.21m |
![]() |
NEW ROLE: Robert Black, Non-Executive Director | 24 Sep 2024 |
![]() |
NEW ROLE: Mark Etherton, Non-Executive Director | 18 Sep 2024 |
![]() |
NEWS: Tagged in Argenica taps investors for $12m | 12 Apr 2024 |
![]() |
NEWS: Tagged in Perth biotech’s stroke drug in nationwide trial | 28 Feb 2024 |
![]() |
NEWS: Tagged in Board Moves December 1, 2023 | 01 Dec 2023 |
![]() |
NEW ROLE: Dianne Angus, Non-Executive Chair | 01 Dec 2023 |
Shares in recruitment firm Hiremii dropped in value by close to 30 per cent today following an overall slump for tech stocks on the ASX.
The Perron Institute is kicking commercial goals, courtesy of big sales royalties and a planned ASX listing.
A Perron Institute spinout focused on reducing brain damage caused by strokes listed on the ASX this morning, with its share price rising 50 per cent.
Our board moves wrap includes Liz Dallimore, Errol Turner, Michael Jordon, Melissa Chapman, Catherine Grant-Edwards, Neil Hutchison, Steve Brockhurst, Karen O'Neill, Darryl Abotomey, Joe D'Addio, Kelly Moore, Jason Livingstone, Trevor Matthews, Bill McKenzie, Dougal Ferguson, and Sylvia Moss.
Perth-based biotechnology company Argenica Therapeutics has secured a $1.2 million grant from the Federal Government.
The state government has awarded $4.3 million to nine health and medical projects, including developing new therapy for liver cancer and delaying Alzheimer’s disease progression.
Our board moves wrap includes Peter Huston, John Welborn, Ian Middlemas, Samantha South, and Benjamin Jarvis.
Our weekly appointments wrap includes Graeme Morissey, Celina Chew, Jason Leeder, Nolan Hunter, Carol Innes, Pennee Osmond, Katie Winterbourne, Brooke Draper, Robert Taylor, Pat Furlong and Brian Rafferty.
Our board moves wrap includes Dianne Angus, Geoff Pocock, Andrew Chapman, Tod McGrouther, Gaurav Gupta, Mark Licciardo, Joel Ives, Karen Logan, Joan Dabon, Harry Spindler, Dan Robinson, Stephen Parker, Ross Walker, Stephen Carter, Grant Lukey, Rhett Morson, Bruce Rathie, Alec PIsmiris, Geoff Stalley, Kenneth Hall, Cathy Moises, and Brady Hall.
Perth biotech company Argenica Therapeutics’ drug, which is designed to reduce brain tissue death following a stroke, will be administrated at two local hospitals in a nationwide trial.
Shares in Argenica Therapeutics were down by 13 per cent on Friday morning, despite the biotechnology technology announcing it would raise $12 million in order to complete its second phase trial of its ARG 007 drug in ischaemic stroke patients.
Access to our data for Argenica Therapeutics is only available to paid subscribers with Data & Insights access.
Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.
Argenica Therapeutics is included in 1 list - Public Companies - Industrial WA.
For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.